In recent years, bispecific antibodies (bsAb) have emerged as promising tools for a target-specific redirection of T cells in order to eliminate malignant cells. However, CD3-engaging constructs might also activate T regulatory cells (Tregs) present in the tumor microenvironment. Whether this has detrimental or beneficial effects for tumor therapy is still controversially discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404924 | PMC |
| http://dx.doi.org/10.4161/2162402X.2014.994441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations.
BMJ Open Ophthalmol
January 2025
Ophthalmology & Vision Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Dual inhibition of the angiopoietin (Ang)/Tie and vascular endothelial growth factor (VEGF) signalling pathways in patients with retinal diseases, such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME), may induce greater vascular stability and contribute to increased treatment efficacy and durability compared with treatments that only target the VEGF pathway. Faricimab, a bispecific intravitreal agent that inhibits both VEGF and Ang-2, is the first injectable ophthalmic drug to achieve treatment intervals of up to 16 weeks in Phase 3 studies for nAMD and DME while exhibiting improvements in visual acuity and retinal thickness. Data from real-world studies have supported the safety, visual and anatomic benefits and durability of faricimab, even in patients who were previously treated with other intravitreal agents.
View Article and Find Full Text PDFThe emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas.
Clin Adv Hematol Oncol
December 2024
Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.
The rapid emergence of CD20-targeting T-cell engagers in follicular lymphoma and large B-cell lymphoma has further expanded the treatment options for patients with relapsed or refractory disease. Herein, we review and discuss the standard-of-care products and indications for mosunetuzumab, epcoritamab, and glofitamab. We provide a detailed overview of the registrational clinical trials, as well as a review of ongoing trials and likely future indications.
View Article and Find Full Text PDFNew therapies to treat cardiac amyloidosis.
Curr Opin Cardiol
January 2025
Division of Cardiology, The Amyloidosis Center, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, USA.
Purpose Of Review: Review advancements in therapies for transthyretin (ATTR-CM) and immunoglobulin light chain (AL-CM) cardiac amyloidosis.
Recent Findings: In ATTR-CM, tafamidis remains the cornerstone therapy, with Food and Drug Administration (FDA) approval for over 5 years. Acoramidis, another transthyretin stabilizer, has very recently been FDA-approved following positive results in the ATTRibute-CM trial.
New Potent Inhibitor of Transforming Growth Factor-Beta (TGFβ) Signaling that is Efficacious against Microsatellite Stable Colorectal Cancer Metastasis in Combination with Immune Checkpoint Therapy in Mice.
ACS Pharmacol Transl Sci
January 2025
Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 10, Barcelona 08028, Spain.
Blockade of the TGFβ signaling pathway has emerged from preclinical studies as a potential treatment to enhance the efficacy of immune checkpoint inhibition in advanced colorectal cancer (CRC) and several other types of cancer. However, clinical translation of first-generation inhibitors has shown little success. Here, we report the synthesis and characterization of HYL001, a potent inhibitor of TGFβ receptor 1 (ALK5), that is approximately 9 times more efficacious than the structurally related compound galunisertib, while maintaining a favorable safety profile.
View Article and Find Full Text PDFOpportunities and limitations of B cell depletion approaches in SLE.
Nat Rev Rheumatol
January 2025
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
B cell depletion with rituximab, a chimeric monoclonal antibody that selectively targets B cells by binding CD20, has been used off label in severe and resistant systemic lupus erythematosus (SLE) for over two decades. Several biological mechanisms limit the efficacy of rituximab, including immunological reactions towards the chimeric molecule, increased numbers of residual B cells, including plasmablasts and plasma cells, and a post-treatment surge in B cell-activating factor (BAFF) levels. Consequently, rituximab induces remission in only a proportion of patients, and safety issues limit its use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!